Medexus Pharmaceuticals Inc.
MEDXF
$2.24
-$0.031-1.37%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 108.33M | 109.54M | 104.76M | 108.78M | 113.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 108.33M | 109.54M | 104.76M | 108.78M | 113.05M |
| Cost of Revenue | 44.82M | 46.13M | 44.15M | 46.15M | 47.99M |
| Gross Profit | 63.51M | 63.41M | 60.61M | 62.63M | 65.07M |
| SG&A Expenses | 43.18M | 41.38M | 41.10M | 43.32M | 44.87M |
| Depreciation & Amortization | 7.18M | 6.19M | 5.88M | 5.77M | 5.81M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.41M | 94.50M | 91.94M | 96.51M | 100.27M |
| Operating Income | 11.92M | 15.04M | 12.82M | 12.28M | 12.79M |
| Income Before Tax | 1.44M | 3.19M | 1.51M | 1.12M | 106.00K |
| Income Tax Expenses | -807.00K | -373.00K | -781.00K | 30.00K | 320.00K |
| Earnings from Continuing Operations | 2.25 | 3.56 | 2.30 | 1.09 | -0.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.25M | 3.56M | 2.30M | 1.09M | -214.00K |
| EBIT | 11.92M | 15.04M | 12.82M | 12.28M | 12.79M |
| EBITDA | 19.02M | 21.04M | 18.52M | 17.86M | 18.44M |
| EPS Basic | 0.10 | 0.15 | 0.09 | 0.04 | -0.01 |
| Normalized Basic EPS | 0.13 | 0.20 | 0.16 | 0.08 | 0.05 |
| EPS Diluted | 0.10 | 0.15 | 0.09 | 0.04 | -0.01 |
| Normalized Diluted EPS | 0.13 | 0.20 | 0.16 | 0.08 | 0.05 |
| Average Basic Shares Outstanding | 103.29M | 98.13M | 97.64M | 93.53M | 89.30M |
| Average Diluted Shares Outstanding | 103.29M | 98.13M | 97.64M | 93.53M | 89.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |